Evidence map›Paper›PMID 28834009›Full record

ArticleAngewandte Chemie (International ed. in English)2017

Chemical Synthesis of the Highly Hydrophobic Antiviral Membrane-Associated Protein IFITM3 and Modified Variants.

Thibault J Harmand, Vijaya R Pattabiraman, Jeffrey W Bode

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Thibault J HarmandLaboratorium für Organische Chemie, Department of Chemistry and Applied Biosciences, ETH Zürich, Wolfgang Pauli Strasse 10, 8093, Zürich, Switzerland.
Vijaya R PattabiramanLaboratorium für Organische Chemie, Department of Chemistry and Applied Biosciences, ETH Zürich, Wolfgang Pauli Strasse 10, 8093, Zürich, Switzerland.
Jeffrey W BodeLaboratorium für Organische Chemie, Department of Chemistry and Applied Biosciences, ETH Zürich, Wolfgang Pauli Strasse 10, 8093, Zürich, Switzerland.ORCID 0000-0001-8394-8910

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interferon-induced transmembrane protein 3 (IFITM3) is an antiviral transmembrane protein that is thought to serve as the primary factor for inhibiting the replication of a large number of viruses, including West Nile virus, Dengue virus, Ebola virus, and Zika virus. Production of this 14.5 kDa, 133-residue transmembrane protein, especially with essential posttranslational modifications, by recombinant expression is challenging. In this report, we document the chemical synthesis of IFTIM3 in multi-milligram quantities (>15 mg) and the preparation of phosphorylated and fluorescent variants. The synthesis was accomplished by using KAHA ligations, which operate under acidic aqueous/organic mixtures that excel at solubilizing even the exceptionally hydrophobic C-terminal region of IFITM3. The synthetic material is readily incorporated into model vesicles and forms the basis for using synthetic, homogenous IFITM3 and its derivatives for further studying its structure and biological mode of action.

Indexed as

Amino Acid SequenceChemistry Techniques, SyntheticFluorescent DyesHumansHydrophobic and Hydrophilic InteractionsMembrane ProteinsModels, MolecularPhosphorylationRNA-Binding ProteinsFluorescent DyesIFITM3 protein, humanMembrane ProteinsRNA-Binding Proteinschemical protein synthesisIFITM3KAHA ligationmembrane proteinsprotein modifications

Identifiers

PMID28834009
PMCPMC5658968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.